Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines

Stacy R. Millon, Julie H. Ostrander, J. Quincy Brown, Anita Raheja, Victoria L. Seewaldt, Nirmala Ramanujam

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

This study quantifies uptake of a fluorescent glucose analog, (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose) (2-NBDG), in a large panel of breast cancer cells and demonstrates potential to monitor changes in glycolysis caused by anticancer and endocrine therapies. Expressions of glucose transporter (GLUT 1) and hexokinase (HK I), which phosphorylates 2-NBDG, were measured via western blot in two normal mammary epithelial and eight breast cancer cell lines of varying biological subtype. Fluorescence intensity of each cell line labeled with 100 μM 2-NBDG for 20 min or unlabeled control was quantified. A subset of cancer cells was treated with anticancer and endocrine therapies, and 2-NBDG fluorescence changes were measured. Expression of GLUT 1 was necessary for uptake of 2-NBDG, as demonstrated by lack of 2-NBDG uptake in normal human mammary epithelial cells (HMECs). GLUT 1 expression and 2-NBDG uptake was ubiquitous among all breast cancer lines. Reduction and stimulation of 2-NBDG uptake was demonstrated by perturbation with anticancer agents, lonidamine (LND), and α-cyano-hydroxycinnamate (α-Cinn), respectively. LND directly inhibits HK and significantly reduced 2-NBDG fluorescence in a subset of two breast cancer cell lines. Conversely, when cells were treated with α-Cinn, a drug used to increase glycolysis, 2-NBDG uptake was increased. Furthermore, tamoxifen (tam), a common endocrine therapy, was administered to estrogen receptor positive and negative (ER+/-) breast cells and demonstrated a decreased 2-NBDG uptake in ER+ cells, reflecting a decrease in glycolysis. Results indicate that 2-NBDG uptake can be used to measure changes in glycolysis and has potential for use in early drug development.

Original languageEnglish (US)
Pages (from-to)55-62
Number of pages8
JournalBreast Cancer Research and Treatment
Volume126
Issue number1
DOIs
StatePublished - Feb 1 2011

Fingerprint

Breast Neoplasms
Cell Line
Glycolysis
Therapeutics
Breast
Fluorescence
2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose
Hexokinase
Facilitative Glucose Transport Proteins
Tamoxifen
Estrogen Receptors
Pharmaceutical Preparations
Antineoplastic Agents
Western Blotting
Epithelial Cells
Glucose

Keywords

  • 2-NBDG
  • Breast cancer cell lines
  • Confocal microscopy
  • GLUT 1
  • Tamoxifen

Cite this

Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines. / Millon, Stacy R.; Ostrander, Julie H.; Brown, J. Quincy; Raheja, Anita; Seewaldt, Victoria L.; Ramanujam, Nirmala.

In: Breast Cancer Research and Treatment, Vol. 126, No. 1, 01.02.2011, p. 55-62.

Research output: Contribution to journalArticle

Millon, Stacy R. ; Ostrander, Julie H. ; Brown, J. Quincy ; Raheja, Anita ; Seewaldt, Victoria L. ; Ramanujam, Nirmala. / Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines. In: Breast Cancer Research and Treatment. 2011 ; Vol. 126, No. 1. pp. 55-62.
@article{564490ae61df460387e9f5cfd5b35389,
title = "Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines",
abstract = "This study quantifies uptake of a fluorescent glucose analog, (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose) (2-NBDG), in a large panel of breast cancer cells and demonstrates potential to monitor changes in glycolysis caused by anticancer and endocrine therapies. Expressions of glucose transporter (GLUT 1) and hexokinase (HK I), which phosphorylates 2-NBDG, were measured via western blot in two normal mammary epithelial and eight breast cancer cell lines of varying biological subtype. Fluorescence intensity of each cell line labeled with 100 μM 2-NBDG for 20 min or unlabeled control was quantified. A subset of cancer cells was treated with anticancer and endocrine therapies, and 2-NBDG fluorescence changes were measured. Expression of GLUT 1 was necessary for uptake of 2-NBDG, as demonstrated by lack of 2-NBDG uptake in normal human mammary epithelial cells (HMECs). GLUT 1 expression and 2-NBDG uptake was ubiquitous among all breast cancer lines. Reduction and stimulation of 2-NBDG uptake was demonstrated by perturbation with anticancer agents, lonidamine (LND), and α-cyano-hydroxycinnamate (α-Cinn), respectively. LND directly inhibits HK and significantly reduced 2-NBDG fluorescence in a subset of two breast cancer cell lines. Conversely, when cells were treated with α-Cinn, a drug used to increase glycolysis, 2-NBDG uptake was increased. Furthermore, tamoxifen (tam), a common endocrine therapy, was administered to estrogen receptor positive and negative (ER+/-) breast cells and demonstrated a decreased 2-NBDG uptake in ER+ cells, reflecting a decrease in glycolysis. Results indicate that 2-NBDG uptake can be used to measure changes in glycolysis and has potential for use in early drug development.",
keywords = "2-NBDG, Breast cancer cell lines, Confocal microscopy, GLUT 1, Tamoxifen",
author = "Millon, {Stacy R.} and Ostrander, {Julie H.} and Brown, {J. Quincy} and Anita Raheja and Seewaldt, {Victoria L.} and Nirmala Ramanujam",
year = "2011",
month = "2",
day = "1",
doi = "10.1007/s10549-010-0884-1",
language = "English (US)",
volume = "126",
pages = "55--62",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Uptake of 2-NBDG as a method to monitor therapy response in breast cancer cell lines

AU - Millon, Stacy R.

AU - Ostrander, Julie H.

AU - Brown, J. Quincy

AU - Raheja, Anita

AU - Seewaldt, Victoria L.

AU - Ramanujam, Nirmala

PY - 2011/2/1

Y1 - 2011/2/1

N2 - This study quantifies uptake of a fluorescent glucose analog, (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose) (2-NBDG), in a large panel of breast cancer cells and demonstrates potential to monitor changes in glycolysis caused by anticancer and endocrine therapies. Expressions of glucose transporter (GLUT 1) and hexokinase (HK I), which phosphorylates 2-NBDG, were measured via western blot in two normal mammary epithelial and eight breast cancer cell lines of varying biological subtype. Fluorescence intensity of each cell line labeled with 100 μM 2-NBDG for 20 min or unlabeled control was quantified. A subset of cancer cells was treated with anticancer and endocrine therapies, and 2-NBDG fluorescence changes were measured. Expression of GLUT 1 was necessary for uptake of 2-NBDG, as demonstrated by lack of 2-NBDG uptake in normal human mammary epithelial cells (HMECs). GLUT 1 expression and 2-NBDG uptake was ubiquitous among all breast cancer lines. Reduction and stimulation of 2-NBDG uptake was demonstrated by perturbation with anticancer agents, lonidamine (LND), and α-cyano-hydroxycinnamate (α-Cinn), respectively. LND directly inhibits HK and significantly reduced 2-NBDG fluorescence in a subset of two breast cancer cell lines. Conversely, when cells were treated with α-Cinn, a drug used to increase glycolysis, 2-NBDG uptake was increased. Furthermore, tamoxifen (tam), a common endocrine therapy, was administered to estrogen receptor positive and negative (ER+/-) breast cells and demonstrated a decreased 2-NBDG uptake in ER+ cells, reflecting a decrease in glycolysis. Results indicate that 2-NBDG uptake can be used to measure changes in glycolysis and has potential for use in early drug development.

AB - This study quantifies uptake of a fluorescent glucose analog, (2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose) (2-NBDG), in a large panel of breast cancer cells and demonstrates potential to monitor changes in glycolysis caused by anticancer and endocrine therapies. Expressions of glucose transporter (GLUT 1) and hexokinase (HK I), which phosphorylates 2-NBDG, were measured via western blot in two normal mammary epithelial and eight breast cancer cell lines of varying biological subtype. Fluorescence intensity of each cell line labeled with 100 μM 2-NBDG for 20 min or unlabeled control was quantified. A subset of cancer cells was treated with anticancer and endocrine therapies, and 2-NBDG fluorescence changes were measured. Expression of GLUT 1 was necessary for uptake of 2-NBDG, as demonstrated by lack of 2-NBDG uptake in normal human mammary epithelial cells (HMECs). GLUT 1 expression and 2-NBDG uptake was ubiquitous among all breast cancer lines. Reduction and stimulation of 2-NBDG uptake was demonstrated by perturbation with anticancer agents, lonidamine (LND), and α-cyano-hydroxycinnamate (α-Cinn), respectively. LND directly inhibits HK and significantly reduced 2-NBDG fluorescence in a subset of two breast cancer cell lines. Conversely, when cells were treated with α-Cinn, a drug used to increase glycolysis, 2-NBDG uptake was increased. Furthermore, tamoxifen (tam), a common endocrine therapy, was administered to estrogen receptor positive and negative (ER+/-) breast cells and demonstrated a decreased 2-NBDG uptake in ER+ cells, reflecting a decrease in glycolysis. Results indicate that 2-NBDG uptake can be used to measure changes in glycolysis and has potential for use in early drug development.

KW - 2-NBDG

KW - Breast cancer cell lines

KW - Confocal microscopy

KW - GLUT 1

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=79151480961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79151480961&partnerID=8YFLogxK

U2 - 10.1007/s10549-010-0884-1

DO - 10.1007/s10549-010-0884-1

M3 - Article

C2 - 20390344

AN - SCOPUS:79151480961

VL - 126

SP - 55

EP - 62

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -